TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20066450

Group type: EXPERIMENTAL
Intervention: Infliximab (INF) 5 mg/Kg every 6-8 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg weekly
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg every other week
Number of subjects: 100
Study: 18679412

Group type: EXPERIMENTAL
Intervention: Egg Diet (ED)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Bagel Diet (BD)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Egg (E)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Bagel (B)
Number of subjects: 152
Study: 15591466

Group type: EXPERIMENTAL
Intervention: Fluticasone (125 mug, twice daily for 6 months)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (twice daily for 6 months)
Number of subjects: 26
Study: 12883106

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 41
Study: 10710018

Group type: EXPERIMENTAL
Intervention: Safety City program
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 181
Study: 9344193

Group type: EXPERIMENTAL
Intervention: Unprotected nevi (40 nevi)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Protected nevi (40 nevi)
Number of subjects: 13
Study: 8154129

Group type: EXPERIMENTAL
Intervention: Transthoracic galvanization
Number of subjects: 110
Study: 2948441

Group type: EXPERIMENTAL
Intervention: Oral HD-MPA (900 mg daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intramuscular HD-MPA (1 g IM daily for 5 days, then 1 g twice weekly)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both oral and IM HD-MPA
Number of subjects: 90
Study: 31563980

Group type: EXPERIMENTAL
Intervention: Parent demandingness
Number of subjects: 6391

Group type: EXPERIMENTAL
Intervention: Parent responsiveness
Number of subjects: 6391

Group type: COMPARATOR
Intervention: #Tamojunto intervention
Number of subjects: 6391
Study: 29644906

Group type: EXPERIMENTAL
Intervention: Heated saline nasal irrigation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Room-temperature saline nasal irrigation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Postheated saline irrigation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nasal patency
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 23
Study: 27509571

Group type: EXPERIMENTAL
Intervention: Chewing gum for 15 minutes each hour during hemodialysis
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no chewing gum)
Number of subjects: 61
Study: 24528605

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg (active control)
Number of subjects: 342
Study: 22521528

Group type: EXPERIMENTAL
Intervention: PET/CT guided IMRT
Number of subjects: 58

Group type: COMPARATOR
Intervention: CT guided IMRT
Number of subjects: 58
Study: 20008644

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg orally once daily
Number of subjects: 225
Study: 18327724

Group type: EXPERIMENTAL
Intervention: Information-theoretic approach for binary surrogate and true endpoints
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing methods for binary outcomes
Number of subjects: 0
Study: 16635047

Group type: EXPERIMENTAL
Intervention: Bumetanide 0.5 mg twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bumetanide >0.5 mg twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Trandolapril 0.5 mg daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination therapy (Bumetanide and Trandolapril)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bumetanide and Trandolapril
Number of subjects: 16
Study: 14710962

Group type: EXPERIMENTAL
Intervention: Intentional control over perception of a Necker cube; varying observers' intentions and focus of primary processing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intentional control over perception of a Necker cube; varying the focus of primary processing with a small cube.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intentional control over perception; top-down activation or priming of perceptual representations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intentional control over perception; limits of intentional control.
Number of subjects: 0
Study: 10607943

Group type: EXPERIMENTAL
Intervention: 5 mg melatonin p.o. daily at 2100 h for a full circadian cycle (35-71 days)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8868528

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg b.w. midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: NaCl 0.9% (control)
Number of subjects: 40
Study: 29540589

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 2064

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2064
Study: 27624139

Group type: COMPARATOR
Intervention: CATCH only (Comparison)
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: CATCH plus school garden intervention (Learn, Grow, Eat & Go!)
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: CATCH plus physical activity intervention (Walk Across Texas)
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: CATCH plus LGEG plus WAT (Combined)
Number of subjects: 1369
Study: 24719708

Group type: EXPERIMENTAL
Intervention: Single injection femoral nerve block (SFNB) with 20cc ropivacaine (10mg/cc)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA) with a combination of 300mg ropivacaine, 30mg ketorolac, and 0.5mg epinephrine diluted to 150cc
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single injection femoral nerve block (SFNB)
Number of subjects: 40
Study: 23467860

Group type: EXPERIMENTAL
Intervention: Dabigatran treatment
Number of subjects: 2944
Study: 20090356

Group type: EXPERIMENTAL
Intervention: Direct Trocar (DT) entry
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Veress Needle (VN) entry
Number of subjects: 1000
Study: 18027115

Group type: EXPERIMENTAL
Intervention: Laparoscopic occlusion (bipolar diathermy in 9 cases, clips in 3 cases)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hysteroscopic occlusion (roller ball electrode)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hysteroscopic tubal occlusion
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Second‐look office hysteroscopy in Group B
Number of subjects: 27
Study: 16186436

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 302
Study: 12373047

Group type: EXPERIMENTAL
Intervention: RA approach (new method for transseptal catheterization)
Number of subjects: 102

Group type: COMPARATOR
Intervention: LA approach (control method for transseptal catheterization)
Number of subjects: 102
Study: 9950438

Group type: EXPERIMENTAL
Intervention: Adjuvant active specific immunotherapy (ASI) with an autologous tumour cell‐BCG vaccine, three weekly vaccinations starting 4 weeks after surgery, booster vaccination at 6 months with 10(7) irradiated autologous tumour cells and 10(7) BCG organisms in the first vaccinations.
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group (no adjuvant treatment).
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Adjuvant active specific immunotherapy (ASI) specifically in stage II disease.
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Adjuvant active specific immunotherapy (ASI) overall.
Number of subjects: 254
Study: 8542532

Group type: EXPERIMENTAL
Intervention: Moderately intense aerobic exercise for 30 to 35 minutes, two times per week
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Moderately intense aerobic exercise for 30 to 35 minutes, three times per week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Very light physical activity at home (Control group)
Number of subjects: 50
Study: 2275326

Group type: EXPERIMENTAL
Intervention: Clonidine 4-5 micrograms.kg-1 p.o. in addition to pethidine 1 mg.kg-1 i.m.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pethidine 1 mg.kg-1 i.m. (Control Group)
Number of subjects: 20
Study: 7267490

Group type: EXPERIMENTAL
Intervention: Arteriosonde 1225
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bosomat 11D
Number of subjects: 18

Group type: COMPARATOR
Intervention: Elag Koln BE 237R
Number of subjects: 18

Group type: COMPARATOR
Intervention: Omron HEM 3
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hawksley Random Zero Sphygmomanometer
Number of subjects: 18
Study: 31363925

Group type: EXPERIMENTAL
Intervention: Healthy Activity Program (HAP) - a culturally adapted behavioral activation treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 0
Study: 26616243

Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Two-step mouthwash
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 12
Study: 25468006

Group type: EXPERIMENTAL
Intervention: No illicit drug use (baseline negative; n = 50)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Any illicit drug use (baseline positive; n = 75)
Number of subjects: 125
Study: 24044764

Group type: EXPERIMENTAL
Intervention: TTM of 33°C
Number of subjects: 950

Group type: COMPARATOR
Intervention: TTM of 36°C
Number of subjects: 950
Study: 21463543

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: St. John's wort
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study: 19063650

Group type: EXPERIMENTAL
Intervention: Brochure intervention for parents considering an exemption
Number of subjects: 0
Study: 16732752

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (XR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 60
Study: 15353899

Group type: EXPERIMENTAL
Intervention: Mistletoe extract Iscador treatment (subcutaneously for at least 3 months)
Number of subjects: 1442

Group type: COMPARATOR
Intervention: Conventional therapy alone (control group)
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Mistletoe extract Iscador treatment
Number of subjects: 1442
Study: 11398117

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg twice daily for 3 days (adults and adolescents)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 200 mg twice daily for 3 days (children aged 4-11 years)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 100 mg twice daily for 3 days (children aged 1-3 years)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 100
Study: 9256993

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8329476

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 3442149

Group type: EXPERIMENTAL
Intervention: Hemodilution (Hctr. 29‐27%)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-hemodiluted patients
Number of subjects: 100
Study: 29461070

Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard-care (SC)
Number of subjects: 70
Study: 28237854

Group type: EXPERIMENTAL
Intervention: Relamorelin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 26250743

Group type: EXPERIMENTAL
Intervention: Personality disorder present
Number of subjects: 366

Group type: COMPARATOR
Intervention: No personality disorder
Number of subjects: 366
Study: 23411400

Group type: EXPERIMENTAL
Intervention: Attentional training group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 21907749

Group type: EXPERIMENTAL
Intervention: MVA-B (1×10(8) pfu/dose) administered as 3 intramuscular injections at weeks 0, 4, and 16
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MVA-B (1×10(8) pfu/dose)
Number of subjects: 30
Study: 18462280

Group type: EXPERIMENTAL
Intervention: Outpatient laparoscopic cholecystectomy (OPS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inpatient laparoscopic cholecystectomy (IPS)
Number of subjects: 100
Study: 15940379

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Alendronate 10 mg
Number of subjects: 42
Study: 12230484

Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 93

Group type: COMPARATOR
Intervention: Dextrose
Number of subjects: 93
Study: 10700784

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 1.25 mg and fentanyl 25 micrograms (group A)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 2.5 mg and fentanyl 25 micrograms (group B)
Number of subjects: 49
Study: 7537364

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate therapy
Number of subjects: 57
Study: 2037113

Group type: EXPERIMENTAL
Intervention: GnRH‐a and hMG for IVF treatment with extended follicle growth by 1 day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard follicle growth duration not specified)
Number of subjects: 0
Study: 7125264

Group type: EXPERIMENTAL
Intervention: Ketamine (1.5 mg/kg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg/kg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Midazolam-Ketamine combination (0.15 mg/kg midazolam and 0.75 mg/kg ketamine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Thiopental (4 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 80
Study: 31067121

Group type: EXPERIMENTAL
Intervention: CHAMP+ intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 88
Study: 30882604

Group type: EXPERIMENTAL
Intervention: Firibastat (250 mg b.i.d. for 1 week, uptitrated to 500 mg b.i.d. for 3 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Firibastat
Number of subjects: 34
Study: 28555206

Group type: EXPERIMENTAL
Intervention: Conical connection implants
Number of subjects: 90

Group type: COMPARATOR
Intervention: Internal hex connection implants
Number of subjects: 90
Study: 26686406

Group type: EXPERIMENTAL
Intervention: Elotuzumab 10 mg/kg plus lenalidomide (25 mg) and dexamethasone (40 mg)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Elotuzumab 20 mg/kg plus lenalidomide (25 mg) and dexamethasone (40 mg)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Elotuzumab (both dosages)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 73
Study: 23764722

Group type: COMPARATOR
Intervention: Increased extra‐axonal axial and radial diffusivities in white matter tracts
Number of subjects: 41

Group type: COMPARATOR
Intervention: Decreased axonal water fraction
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: White matter tract integrity metrics in the body of the corpus callosum
Number of subjects: 41
Study: 21434845

Group type: EXPERIMENTAL
Intervention: Trabecular metal cups (Monoblock cup)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Titanium fiber-mesh cups (Trilogy cup)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 19747744

Group type: EXPERIMENTAL
Intervention: Celecoxib (2 x 400 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 17038015

Group type: EXPERIMENTAL
Intervention: P-OSCE
Number of subjects: 72

Group type: COMPARATOR
Intervention: Written Exam
Number of subjects: 72
Study: 12626436

Group type: EXPERIMENTAL
Intervention: Exercise (3 hours of cycling)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Recombinant human IL-6 infusion (3 hours)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (resting)
Number of subjects: 8
Study: 11298543

Group type: EXPERIMENTAL
Intervention: Famciclovir (FCV) 125 mg twice daily for 5 days
Number of subjects: 204

Group type: COMPARATOR
Intervention: Aciclovir (ACV) 200 mg five times daily for 5 days
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both FCV and ACV
Number of subjects: 204
Study: 9402661

Group type: EXPERIMENTAL
Intervention: Selective continuous coronary perfusion via the aortic root with warm esmolol-enriched CPB blood
Number of subjects: 60

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (Bretschneider HTK)
Number of subjects: 60
Study: 8497826

Group type: EXPERIMENTAL
Intervention: Frusemide (5, 10, and 20 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2447411

Group type: EXPERIMENTAL
Intervention: SLOx (slow release oxprenolol) administered in a single evening dose for 7 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo administered for 7 days
Number of subjects: 8
Study: 30326587

Group type: EXPERIMENTAL
Intervention: Sucrose trifle
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Isomaltulose trifle
Number of subjects: 77
Study: 27932822

Group type: EXPERIMENTAL
Intervention: Dental hygienist-therapist only for check-up
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alternating between general dental practitioner and dental hygienist-therapist
Number of subjects: 60

Group type: COMPARATOR
Intervention: General dental practitioner only for check-up
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recruitment rate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Qualitative study
Number of subjects: 60
Study: 24089073

Group type: EXPERIMENTAL
Intervention: Poor metabolizers (PMs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Extensive metabolizers (EMs)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 23488887

Group type: EXPERIMENTAL
Intervention: Social prompting intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modeling intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study: 21178422

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guidance for antibiotic therapy
Number of subjects: 0
Study: 18005195

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EG) - 3 cups of Clinutren fruit, 2 boxes of OPD Elemental 028 extra, 2 cups of OPD Peptamen, 1000 ml isotonic cristalloid solution, allowed to drink up to 1000 ml of tea or water per 24 h
Number of subjects: 32

Group type: COMPARATOR
Intervention: Parenteral nutrition (PG) - 1250 ml Nutriflex lipid basal intravenously, 1000 ml isotonic cristalloid solution, allowed to drink up to 1000 ml of tea or water per 24 h
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Parenteral nutrition (PG)
Number of subjects: 32
Study: 16637520

Group type: EXPERIMENTAL
Intervention: Terumo X-Coating (PMEA surface coating)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cobe Smart-X coating (SMA surface coating)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Terumo noncoated tubing (NCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cobe noncoated tubing (NCC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SMA and PMEA circuits
Number of subjects: 30
Study: 14644221

Group type: EXPERIMENTAL
Intervention: Ketotifen 0.025% eye drops
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 11030486

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15‐45 mg/day)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Paroxetine (20‐40 mg/day)
Number of subjects: 275
Study: 8642153

Group type: EXPERIMENTAL
Intervention: Home-based strength training program (Strong-for-Life) for 12 to 15 weeks
Number of subjects: 102
Study: 2123370

Group type: EXPERIMENTAL
Intervention: Norethindrone-containing TOC
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing TOC
Number of subjects: 28
Study: 350232

Group type: EXPERIMENTAL
Intervention: 75 mg daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 150 mg daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 300 mg daily
Number of subjects: 135
Study: 30757926

Group type: EXPERIMENTAL
Intervention: Cervicothoracic junction manual therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Upper-cervical manual therapy
Number of subjects: 22
Study: 31277991

Group type: EXPERIMENTAL
Intervention: Guy2Guy mHealth HIV prevention program
Number of subjects: 302
Study: 27438055

Group type: EXPERIMENTAL
Intervention: Uresta device
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo vaginal silastic ring
Number of subjects: 36
Study: 24819997

Group type: EXPERIMENTAL
Intervention: 30 minutes of time at work to exercise
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Comfortable taking time off to exercise
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Too much work
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Job satisfaction and ability to take time off for personal matters
Number of subjects: 188
Study: 23429692

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bupropion HCl
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 48
Study: 21641635

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SCIT plus SLIT
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SCIT and SLIT
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SCIT and SCIT plus SLIT
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SLIT
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Clinical symptom scores
Number of subjects: 51